Executive SummaryRobert Nowinski, PhD, to VP-new technology. Science & Technology Group. He continues as a corporate VP and president of subsidiary Genetic Systems. Nowinski was a founder of Genetic Systems, acquired by Bristol in 1986; Marvin Gorman, PhD, to exec VP of biotech research subsidiary Oncogen; Charles Heimbold, president of B-M's Health Care (non-pharmaceutical) Group, will assume corporate responsibility for planning and development, succeeding John Melton, who has resigned.
You may also be interested in...
As part of its response to the coronavirus outbreak, the European association representing generic and biosimilar drug companies, Medicines for Europe, has set out a series of policy recommendations that it says could help to mitigate the possible risks to medicines supply.
Podcast: Living In China's Coronavirus Lockdown, Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.